Accumulated number of Neuramis exceeded 12 million syringes
Launched a hangover relief probiotics, Khan’s Morning
Began third open recruitment
Began phase 3 trials of new formulation of botulinum toxin type A in EU by Allergan Inc. (US)
Selected as “2019 Asia’s Most Trusted Company”
Began phase 3 trials of new formulation of botulinum toxin type A in US, Canada by Allergan Inc. (US)
Received the presidential commendation award at the 2018 Governor's Job Creation Awards (Ministry of Employment and Labor)
Selected as “2018 the Best Job Creation Company in Korea” (Ministry of Employment and Labor)
Neuronox and Neuramis, selected as “Korean World-class Products Awards 2018” (Ministry of Trade and Industry)
Started Global CSR Campaign ‘Team 2022’
Began second open recruitment
Received $100M Export Tower Award
Began first open recruitment
Completed Medytox Gwanggyo R&D Center construction
Established a Thailand joint venture "MedyCeles"
Relocated to Medytox Building (Daechi-dong, Gangnam-gu, Seoul)
Received $30M Export Tower Award
Exceeded 100 billion KRW mark in total annual sales
Completed Medytox Plant III (Osong) construction, the biggest scale in Korea
Obtained drug approval for non-animal-derived botulinum toxin type A which refined only main active ingredients, Coretox® 100U
Started a scholarship program to support talents for the fields of life science in Korea
Selected as Forbes "Asia’s 200 Best Under a Billion List 2015"
Received $20M Export Tower Award
Received "Minister of Industry Commendation" on 5th Industrial Technology Protection Day
Received the "Presidential Commendation of Technology Development Division with Special Merit" (Ministry of Trade, Industry, and Energy)
Received the "Best Trader of the 2015 Award" (Ministry of Trade, Industry, and Energy, Korea International Trade Association)
Obtained approval from MFDS for Neuramis® Lidocaine Series
Obtained approval from MFDS for Innotox® 50U
Established a Japan local subsidiary "MDT International Inc."
Established a Hong Kong joint venture "Medytox Hong Kong"
Established a China joint venture "Medybloom China"
Established a Taiwan joint venture "Medytox Taiwan"
Obtained approval from MFDS for Neuramis® Deep Lidocaine
Selected as "K-Brain Power" (Ministry of Trade, Industry, and Energy)
Received the Grand Prize at the "6th Korea Technology Award" (Ministry of Trade, Industry, and Energy)
cGMP / EU GMP compliant Medytox Plant II (Osong) construction